share_log

贵州三力(603439.SH):拟受让汉方药业22.9111%股权

guizhou sanli pharmaceutical co.,ltd. (603439.SH): plans to acquire 22.9111% equity of Hanfang Pharmaceutical

Gelonghui Finance ·  Dec 3, 2024 17:32

On December 3, Gelonhui reported that guizhou sanli pharmaceutical co.,ltd. (603439.SH) announced that the company intends to acquire Mr. Deng Daixing's 22.9111% equity stake in Guizhou Hanfang Pharmaceutical Co., Ltd. (referred to as "Hanfang Pharmaceutical"). The equity transfer price for this transfer is RMB 169.83 million, to be paid in cash. As of the date before this equity transfer, Hanfang Pharmaceutical was a controlling subsidiary of the company, with the company holding 75.8928% equity stake in it; after the completion of this equity transfer, the company will hold 98.8039% equity stake in Hanfang Pharmaceutical.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment